Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001636587-25-000045
Filing Date
2025-08-15
Accepted
2025-08-15 10:31:34
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10572
  Complete submission text file 0001636587-25-000045.txt   12285
Mailing Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 301 PRINCETON NJ 08540 646-885-8505
Y-mAbs Therapeutics, Inc. (Subject) CIK: 0001722964 (see all company filings)

EIN.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90649 | Film No.: 251222911
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 295 MADISON AVENUE 32ND FL NEW YORK NY 10017
Business Address 295 MADISON AVENUE 32ND FL NEW YORK NY 10017 917-940-2732
ACORN BIOVENTURES, L.P. (Filed by) CIK: 0001766853 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A